EMA Recommends Granting a Marketing Authorisation for Accordpharma Enzalutamide By Ogkologos - December 5, 2025 230 0 Facebook Twitter Google+ Pinterest WhatsApp It is a generic and hybrid of Xtandi, which has been authorised in the EU since 2013 Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Generic Palbociclib Metastasis-Directed Therapy for Oligometastatic Solid Tumours in Histology-Specific Context ctDNA Testing After Neoadjuvant Chemotherapy and Radical Cystectomy Predicts Recurrence Risk in Patients with MIBC MOST POPULAR Race for Life events are back this autumn June 25, 2021 Brentuximab Approved for High-Risk Hodgkin Lymphoma in Children and Adolescents December 15, 2022 How we are working with industry to translate research into real... April 26, 2022 Survey results reveal attitudes towards cancer screening during the pandemic July 16, 2021 Load more HOT NEWS Trastuzumab Deruxtecan Shows Promising Activity Among Patients with HER2-positive and Signal... “Scars are Tattoos with Better Stories” FDA Approves Daratumumab and Hyaluronidase-fihj with Bortezomib, Lenalidomide, and Dexamethasone for... How Alcohol Increases Your Cancer Risk and What to Know About...
